BARCELONA, Spain and DÜSSELDORF, Germany, November 27, 2025 — Leads & Copy —
Neuraxpharm Group, a European specialty pharmaceutical company focused on central nervous system (CNS) disorders, and mjn-neuro, a start-up specializing in AI-driven neurotechnology, have announced plans to launch EPISERAS®, a digital health solution designed to predict the risk of epileptic seizures in real time. The launch, expected to begin in the second half of 2026, will consolidate Neuraxpharm’s entry into the medical devices and digital health space.
EPISERAS® is a non-invasive medical device that continuously records brain activity through a discreet, wearable earpiece sensor. Utilizing advanced artificial intelligence (AI) algorithms, it analyzes electrical patterns in the brain to identify when a seizure is likely to occur and sends an alert minutes before the seizure is expected to happen when risk levels are high. The device connects to a dedicated mobile application that analyzes and displays seizure-risk data and notifications, supporting patients and caregivers in daily monitoring.
The solution is designed for use in patients with drug-resistant epilepsy, offering a proactive tool to help prevent accidents and improve safety in daily life. It has already been validated and certified in Europe as a medical device Class IIa, holding the CE mark and UKCA certification.
A multicenter, prospective clinical study, SERAS-Home_RWD, is underway across Spain, the United Kingdom, and Germany. Interim data from the study is being prepared for publication.
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, emphasized the company’s commitment to improving the lives of people with CNS disorders through continuous innovation and strong partnerships, taking another important step in their journey to improve the daily lives of people with epilepsy. Dr. Dierks said this breakthrough embodies Neuraxpharm’s commitment to digital personalized CNS care, helping patients feel safer, more in control, and better supported.
David Blánquez, CEO and Co-Founder of mjn-neuro, stated that his team has been developing this pioneering project for more than ten years. He said, thanks to the results obtained from several clinical studies, mjn-neuro has successfully demonstrated solid clinical evidence supporting its effectiveness. Blánquez said his company is focused on ensuring that patients can benefit from this innovation that will help improve their quality of life and reduce accidents caused by seizures. He noted that working with Neuraxpharm on the European market launch is a key step in bringing this breakthrough solution to those who need it most.
Neuraxpharm first partnered with mjn-neuro in 2022, marking its entry into the wearable technology space. This initiative demonstrates Neuraxpharm’s commitment to advancing breakthrough innovation across both pharmacological and technology-driven approaches to CNS care.
References:
1 EU Medical Device Regulation (EU MDR) certificate 777314
2 UKCA Class IIa certificate 777308
3 MJN Neuroserveis, S.L. (2024). Evaluation of the epilepsy-related quality of life, seizure-related accidents and validation of the mjn-SERAS solution in the normalised patient environment with real-world data (SERAS_Home_RWD) [Clinical trial]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05845255
About EPISERAS®
EPISERAS® is a non-invasive medical digital solution that continuously records brain activity through a discreet, wearable earpiece sensor. Using advanced artificial intelligence algorithms, the solution analyses electrical patterns in the brain for the early identification of when a seizure is likely to occur and sends an alert when risk levels are high. This early warning enables patients to take preventive action, such as moving to a safe place or notifying caregivers, thereby reducing the risk of accidents and improving quality of life. 1
About the Neuraxpharm Group
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders, with a unique understanding of the CNS market.
Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions.
The company has c.1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, in Australia and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira.
Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain.
About mjn-neuro
mjn-neuro is a Girona-based start-up founded in 2014 that designs, manufactures and markets medical devices with the aim of improving people’s quality of life. The company’s first product worldwide is the mjn-SERAS (EPISERAS®) medical device, which provides early warning of an epileptic seizure. The device has been developed from 2018 and tested in several clinical trials.
mjn-neuro continues working on new solutions for other neurological diseases based on new technology and artificial intelligence algorithms, in collaboration with clinical and technological centers. mjn-neuro is in close exchange with the medical side, which allows the company to understand the problems and needs of doctors and patients and help find the best solutions to address them, either through devices, technology or artificial intelligence solutions.
No contact information provided.
Source: Neuraxpharm Group
